NPS CEO gives insight into orphan drug pricing

01/7/2013 | Forbes

When pricing a new biologic drug, developers consider medical value, direct and indirect costs, market size and insurers' willingness to pay, NPS Pharmaceuticals CEO Francois Nader said. In the case of drugs to treat rare diseases, such as NPS' Gattex, NPS will give grants to rare-disease organizations that will help patients pay, and the company will offer copay assistance.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY